Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice (Q33851826)

29 July 2017

1 reference

title

Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice (English)

1 reference

29 July 2017

Fortune JM

1

1 reference

PubMed ID

10697411

29 July 2017

Osheroff N

series ordinal

2

1 reference

29 July 2017

1 January 2000

1 reference

Progress in Molecular Biology and Translational Science

29 July 2017

1 reference

29 July 2017

64

1 reference

29 July 2017

221-253

1 reference

Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Structure of plectonemically supercoiled DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

1 reference

7 January 2021

Investigating the biological functions of DNA topoisomerases in eukaryotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

The structure of supercoiled intermediates in DNA replication

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Biochemical basis for the interactions of type I and type II topoisomerases with DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

1 reference

7 January 2021

Bacterial and archeal type I topoisomerases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

A model for the mechanism of human topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Domains of human topoisomerase I and associated functions.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Vaccinia virus DNA topoisomerase: a model eukaryotic type IB enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Supercoiling of the DNA template during transcription

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Transcription generates positively and negatively supercoiled domains in the template.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Control of bacterial DNA supercoiling

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

The twisted 'life' of DNA in the cell: bacterial topoisomerases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Targeted disruption of the mouse topoisomerase I gene by camptothecin selection

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Structure and function of type II DNA topoisomerases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

ATP-dependent DNA topoisonmerase from D. melanogaster reversibly catenates duplex DNA rings

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Mitotic spindle pulls but fails to separate chromosomes in type II DNA topoisomerase mutants: uncoordinated mitosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Disassembly of the nucleus in mitotic extracts: membrane vesicularization, lamin disassembly, and chromosome condensation are independent processes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Mitotic chromatin condensation in vitro using somatic cell extracts and nuclei with variable levels of endogenous topoisomerase II.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Chromosome assembly in vitro: Topoisomerase II is required for condensation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Topoisomerase II is a structural component of mitotic chromosome scaffolds.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Localization of topoisomerase II in mitotic chromosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Metaphase chromosome structure. Involvement of topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Structure of the Drosophila DNA topoisomerase II gene. Nucleotide sequence and homology among topoisomerases II.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Structure and mechanism of DNA topoisomerases.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Structure of DNA topoisomerases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Functional dissection of the phosphorylated termini of fission yeast DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Bipartite nuclear localization signals in the C terminus of human topoisomerase II alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Nuclear distribution of human DNA topoisomerase IIbeta: a nuclear targeting signal resides in the 116-residue C-terminal tail.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Yeast DNA topoisomerase II is encoded by a single-copy, essential gene

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Eukaryotic DNA topoisomerase II beta.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Essential mitotic functions of DNA topoisomerase IIalpha are not adopted by topoisomerase IIbeta in human H69 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Physiological regulation of eukaryotic topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Topoisomerase II: A specific marker for cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Role of the divalent cation in topoisomerase II mediated reactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Sequence dependence of Drosophila topoisomerase II in plasmid relaxation and DNA binding.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria. Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Characterization of the interaction between topoisomerase II and DNA by transcriptional footprinting

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Drosophila topoisomerase II double-strand DNA cleavage: analysis of DNA sequence homology at the cleavage site

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

A consensus sequence for cleavage by vertebrate DNA topoisomerase II.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Catalytic function of DNA topoisomerase II.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

DNA sequence selectivity of topoisomerases and topoisomerase poisons.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Strand specificity of the topoisomerase II mediated double-stranded DNA cleavage reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Incomplete reversion of double stranded DNA cleavage mediated by Drosophila topoisomerase II: formation of single stranded DNA cleavage complex in the presence of an anti-tumor drug VM26

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Saccharomyces cerevisiae nuclear fusion requires prior activation by alpha factor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Uncoupling the DNA cleavage and religation activities of topoisomerase II with a single-stranded nucleic acid substrate: evidence for an active enzyme-cleaved DNA intermediate

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Topoisomerase II-mediated DNA cleavage and religation in the absence of base pairing. Abasic lesions as a tool to dissect enzyme mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Structure and mechanism of DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 1. A DNA-dependent burst in ATP hydrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 2. Kinetic mechanism for the sequential hydrolysis of two ATP

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Topoisomerase II alpha is associated with the mammalian centromere in a cell cycle- and species-specific manner and is required for proper centromere/kinetochore structure

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Untangling the role of DNA topoisomerase II in mitotic chromosome structure and function.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Eukaryotic topoisomerase II preferentially cleaves alternating purine-pyrimidine repeats

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

In vitro evolution of preferred topoisomerase II DNA cleavage sites

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II. I. m-AMSA.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Mutagenic properties of topoisomerase-targeted drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

DNA topoisomerases: essential enzymes and lethal targets

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Cell death induced by topoisomerase-targeted drugs: more questions than answers

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Topoisomerase poisons: harnessing the dark side of enzyme mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Topoisomerase inhibitors. A review of their therapeutic potential in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Clinical applications of anticancer drugs targeted to topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Fluoroquinolone antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

DNA gyrase as a drug target

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Clinical applications of quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Protein-associated DNA breaks in cells treated with adriamycin or ellipticine

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Qualitative and quantitative aspects of intercalator-induced DNA strand breaks

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Drug resistance associated with altered DNA topoisomerase II.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Using yeast to understand drugs that target topoisomerases.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Using yeast to study resistance to topoisomerase II-targeting drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

A yeast type II topoisomerase selected for resistance to quinolones. Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Osteosarcomas and adult soft tissue sarcomas: Is there a place for high LET radiation therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

The critical role of chromosome translocations in human leukemias.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Secondary leukemias induced by topoisomerase-targeted drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Topoisomerase IV catalysis and the mechanism of quinolone action.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Streptonigrin-induced topoisomerase II sites exhibit base preferences in the middle of the enzyme stagger

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

The response of eukaryotic topoisomerases to DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Histidine 289 is essential for hydrolysis of the alkyl-enzyme intermediate of haloalkane dehalogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Apurinic sites are position-specific topoisomerase II poisons.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Spontaneous DNA lesions poison human topoisomerase IIalpha and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Instability and decay of the primary structure of DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

DNA Modification and Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Mechanism of action of quinolones against Escherichia coli DNA gyrase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Increased drug affinity as the mechanistic basis for drug hypersensitivity of a mutant type II topoisomerase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

DNA topoisomerase II mutations and resistance to anti-tumor drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the c

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Antitopoisomerase drug action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Topoisomerase II cleavage in chromatin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Modulation of gyrase-mediated DNA cleavage and cell killing by ATP.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Initial mechanistic studies with merbarone (NSC 336628)

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). The MST-16 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Catalytic inhibitors of DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Effects of the DNA topoisomerase II inhibitor merbarone in male mouse meiotic divisions in vivo: cell cycle arrest and induction of aneuploidy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Inhibition of type II topoisomerase by fostriecin

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Mitindomide is a catalytic inhibitor of DNA topoisomerase II that acts at the bisdioxopiperazine binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

The interaction between coumarin drugs and DNA gyrase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Analysis of a core domain in Drosophila DNA topoisomerase II. Targeting of an antitumor agent ICRF-159.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Appendix. II: Alignment of primary sequences of DNA topoisomerases.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6603%2800%2964006-0

7 January 2021

10.1016/S0079-6603(00)64006-0

Identifiers

DOI

1 reference

release_vfgjs56lkrewxhiud3iwbpocoi

29 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vfgjs56lkrewxhiud3iwbpocoi

24 November 2022

mapped directly with Wikidata item

PubMed ID

10697411

1 reference

PubMed ID

10697411